These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. Hunt BJ, Segal HC, Yacoub M. J Thorac Cardiovasc Surg; 1992 Jul; 104(1):211-2. PubMed ID: 1377315 [No Abstract] [Full Text] [Related]
23. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Huyzen RJ, van Oeveren W, Wei F, Stellingwerf P, Boonstra PW, Gu YJ. Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618 [Abstract] [Full Text] [Related]
26. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass. Barnette RE, Shupak RC, Pontius J, Rao AK. Anesth Analg; 1988 Jan; 67(1):57-60. PubMed ID: 3257361 [Abstract] [Full Text] [Related]
27. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy. Feindt P, Volkmer I, Seyfert U, Huwer H, Kalweit G, Gams E. Thorac Cardiovasc Surg; 1993 Feb; 41(1):9-15. PubMed ID: 7690165 [Abstract] [Full Text] [Related]
28. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Najman DM, Walenga JM, Fareed J, Pifarré R. Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854 [Abstract] [Full Text] [Related]
29. Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass. Gu YJ, Huyzen RJ, van Oeveren W. Anesth Analg; 1996 Aug; 83(2):433. PubMed ID: 8694335 [No Abstract] [Full Text] [Related]
32. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery. Kim YS, Murkin JM, Adams SJ. Heart Surg Forum; 2004 Aug; 7(6):E599-604. PubMed ID: 15769695 [Abstract] [Full Text] [Related]
33. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time. Dong Y, Nuttall GA, Oliver WC, Agarwal S, Ereth MH. J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670 [Abstract] [Full Text] [Related]
34. Platelet involvement in the activated coagulation time of heparinized blood. Moorehead MT, Westengard JC, Bull BS. Anesth Analg; 1984 Apr; 63(4):394-8. PubMed ID: 6367544 [Abstract] [Full Text] [Related]
37. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT. Ganter MT, Dalbert S, Graves K, Klaghofer R, Zollinger A, Hofer CK. Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133 [Abstract] [Full Text] [Related]
38. Coagulopathy screening in children with heparinized central venous catheters. Ellis MR. Pediatrics; 1993 Jun; 91(6):1147-50. PubMed ID: 8502518 [Abstract] [Full Text] [Related]
39. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ. Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479 [Abstract] [Full Text] [Related]